5/17/2023 0 Comments Capto q column![]() ![]() brasiliensis since these compounds were identified for the first time in the stems of this species. This study contributes to the phytochemical study of S. The EE, DCMF, ACF, and HEF exhibited great antioxidant potential by DPPH (IC 50 1.71 – 32.83 µg/mL) and FRAP (IC 50 0.63 – 6,71 µg/mL) assays. The EE, DCMF, and ACF showed high total contents of phenolic compounds (112.99, 175.71, and 524.02 µg of GAE/mg, respectively), and in the ACF and DCMF a great content of flavonoids was also quantified (50.08 and 31.49 µg of QE/mg, respectively). The EE and DCMF, ACF, and HEF were analyzed by liquid chromatography coupled to a diode array detector and mass spectrometer (LC–DAD–MS), and the identified constituents included glycosylated (rutin, 3- O-β-galactopyranosyl quercetin, 3- O-β-glucopyranosyl quercetin, O-deoxyhexosyl-hexosyl quercetin, O-deoxyhexosyl-hexosyl kaempferol, O-deoxyhexosyl-hexosyl O-methyl quercetin, and others), and non-glycosylated (quercetin) flavonoids, phenylpropanoids (3- O- E-caffeoyl quinic acid, 5- O- E-caffeoyl quinic acid, O-caffeoyl shikimic acid, and others), neolignan, steroidal saponin (dioscin), and N-feruloyltyramine. Fatty acid esters, hydrocarbons, and phytosterols were identified in the HEXF analyzed by gas chromatography – mass spectrometry (GC–MS). The chemical composition was determined, the contents of phenolic compounds and flavonoids were quantified, and the antioxidant potential and the cytotoxic effect on Artemia salina were evaluated. ![]() In this study, the ethanol extract (EE) and the hexane (HEXF), dichloromethane (DCMF), ethyl acetate (ACF), and hydroethanol (HEF) fractions of the stems were obtained. Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.Smilax brasiliensis Sprengel is a monocotyledon of the Smilacaceae family, native to the Brazilian Cerrado, popularly known as “salsaparrilha” or “japecanga”. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. As part of the GE Healthcare BioProcess™ media platform, Capto ImpRes ion exchangers are manufactured under validated production methods, backed up with Regulatory Support Files, and have Secure Supply routines in place. ![]() "Capto ImpRes media have been designed to meet the throughput and high resolution needs of intermediate purification and polishing."Ĭapto ImpRes media are available in several convenient formats, including Predictor™ 96-well filter plates and prepacked HiTrap™ and HiScreen™ columns to support all stages of biopharmaceutical development and manufacture. "The extension of the Capto platform with Capto ImpRes ion exchangers demonstrates our commitment to supporting biopharmaceutical manufacturers with the most modern tools to improve their processes in terms of throughput, productivity, and economy," said Dr Nigel Darby, Vice President, Biotechnologies, GE Healthcare. The first Capto ImpRes products to be launched are Capto SP ImpRes and Capto Q ImpRes, strong cation and strong anion exchangers, respectively, that enable high throughput, high resolution polishing, and flexibility in process design.Ĭapto ImpRes media are based on a rigid high-flow agarose matrix that allows the use of high flow rates and higher bed heights, providing biopharmaceutical manufacturers with the possibility to reduce cycle times and maintain or reduce column equipment footprint, thus contributing to driving improvements in process economics. Uppsala, Sweden – GE Healthcare, a unit of General Electric Company (NYSE: GE), announced today that the capabilities of the well-established Capto platform are now extended to include Capto ImpRes ion exchange chromatography media for late-stage purification of a wide range of biomolecules. ![]()
0 Comments
Leave a Reply. |